These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 9171881)
1. 7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors. Ohkawa S; DiGiacomo B; Larson DL; Takemori AE; Portoghese PS J Med Chem; 1997 May; 40(11):1720-5. PubMed ID: 9171881 [TBL] [Abstract][Full Text] [Related]
2. 7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands. Fang X; Larson DL; Portoghese PS J Med Chem; 1997 Sep; 40(19):3064-70. PubMed ID: 9301669 [TBL] [Abstract][Full Text] [Related]
3. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329 [TBL] [Abstract][Full Text] [Related]
4. Synthesis of 7-arylmorphinans. Probing the "address" requirements for selectivity at opioid delta receptors. Gao P; Larson DL; Portoghese PS J Med Chem; 1998 Jul; 41(16):3091-8. PubMed ID: 9685249 [TBL] [Abstract][Full Text] [Related]
5. 14-Desoxy analogues of naltrindole and 7-spiroindanyloxymorphone: the role of the 14-hydroxy group at delta opioid receptors. Kshirsagar TA; Fang X; Portoghese PS J Med Chem; 1998 Jul; 41(14):2657-60. PubMed ID: 9651172 [TBL] [Abstract][Full Text] [Related]
6. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores. Lenard NR; Daniels DJ; Portoghese PS; Roerig SC Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633 [TBL] [Abstract][Full Text] [Related]
7. Characterization of kappa and delta opioid receptors in isolated organs by using type/subtype selective agonists and antagonists. Makó E; Rónai AZ Med Sci Monit; 2001; 7(3):350-6. PubMed ID: 11386008 [TBL] [Abstract][Full Text] [Related]
8. Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective delta agonist (+)-4-[(alpha R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,N-diethylbenzamide (SNC 80) and related novel nonpeptide delta opioid receptor ligands. Calderon SN; Rice KC; Rothman RB; Porreca F; Flippen-Anderson JL; Kayakiri H; Xu H; Becketts K; Smith LE; Bilsky EJ; Davis P; Horvath R J Med Chem; 1997 Feb; 40(5):695-704. PubMed ID: 9057856 [TBL] [Abstract][Full Text] [Related]
9. Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists. Katsura Y; Zhang X; Homma K; Rice KC; Calderon SN; Rothman RB; Yamamura HI; Davis P; Flippen-Anderson JL; Xu H; Becketts K; Foltz EJ; Porreca F J Med Chem; 1997 Aug; 40(18):2936-47. PubMed ID: 9288176 [TBL] [Abstract][Full Text] [Related]
10. Effects of some 7-arylidene and 7-heteroarylidene morphinan-6-ones on the antinociceptive activity of [D-Pen2, D-Pen5]enkephalin and [D-Ala2, Glu4]deltorphin II and on multiple opioid receptors. Bhargava HN; Zhao GM; Bian JT; Nan Y; Upadhyaya SP; Xu W; Dunn WJ; Bauer L Peptides; 1997; 18(5):695-701. PubMed ID: 9213363 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety. Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975 [TBL] [Abstract][Full Text] [Related]
12. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans. Ananthan S; Kezar HS; Carter RL; Saini SK; Rice KC; Wells JL; Davis P; Xu H; Dersch CM; Bilsky EJ; Porreca F; Rothman RB J Med Chem; 1999 Sep; 42(18):3527-38. PubMed ID: 10479286 [TBL] [Abstract][Full Text] [Related]
16. De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the delta-opioid receptor. Liao S; Alfaro-Lopez J; Shenderovich MD; Hosohata K; Lin J; Li X; Stropova D; Davis P; Jernigan KA; Porreca F; Yamamura HI; Hruby VJ J Med Chem; 1998 Nov; 41(24):4767-76. PubMed ID: 9822547 [TBL] [Abstract][Full Text] [Related]
17. In vitro potency, affinity and agonist efficacy of highly selective delta opioid receptor ligands. Kramer TH; Davis P; Hruby VJ; Burks TF; Porreca F J Pharmacol Exp Ther; 1993 Aug; 266(2):577-84. PubMed ID: 8394911 [TBL] [Abstract][Full Text] [Related]
18. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors. Liu JG; Prather PL J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665 [TBL] [Abstract][Full Text] [Related]
19. A selective delta 1 opioid receptor agonist derived from oxymorphone. Evidence for separate recognition sites for delta 1 opioid receptor agonists and antagonists. Portoghese PS; Moe ST; Takemori AE J Med Chem; 1993 Aug; 36(17):2572-4. PubMed ID: 8394935 [No Abstract] [Full Text] [Related]
20. Comparison of cyclic delta-opioid peptides with non-peptide delta-agonist spiroindanyloxymorphone (SIOM) using the message-address concept: a molecular modeling study. Gao P J Comput Aided Mol Des; 1996 Aug; 10(4):327-36. PubMed ID: 8877704 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]